Cattori Valentino, Tandon Ravi, Pepin Andrea, Lutz Hans, Hofmann-Lehmann Regina
Clinical Laboratory, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, CH-8057 Zurich, Switzerland.
Mol Cell Probes. 2006 Jun-Aug;20(3-4):172-81. doi: 10.1016/j.mcp.2005.11.007. Epub 2006 Feb 20.
Feline leukemia virus (FeLV) is a gamma retrovirus that induces fatal diseases in domestic cats. Efficacious FeLV vaccines prevent persistent viremia and development of FeLV-related disease after virus exposure, but not minimal viral replication and a provirus-positive state as recently demonstrated using sensitive real-time PCR assays. Proviral integration is an important parameter of latent infection and persistence of retroviruses in infected cells. So far, FeLV-specific real-time PCR assays could not distinguish between the integrated and episomal forms of the provirus. Thus, it was the aim of the present study to develop a rapid assay for the detection of FeLV proviral integration. The test combines conventional and quantitative real-time PCR that use virus-specific primers and primers specific for cat genomic small interspersed nuclear elements. It was applied to analyze the time course of proviral integration into the genome of a feline fibroblast cell line and detect provirus integration in peripheral white blood cells from vaccinated and unvaccinated, FeLV-exposed cats. The newly developed rapid test will essentially contribute to a better understanding of the mechanisms involved in the pathogenesis of FeLV infection and be especially useful in the development of antiretroviral vaccines and therapies aimed at the inhibition of proviral integration.
猫白血病病毒(FeLV)是一种γ逆转录病毒,可在家猫中引发致命疾病。有效的FeLV疫苗可预防病毒暴露后出现持续性病毒血症以及FeLV相关疾病的发展,但正如最近使用灵敏的实时PCR检测所证明的那样,不能预防最低限度的病毒复制和前病毒阳性状态。前病毒整合是逆转录病毒在受感染细胞中潜伏感染和持续存在的一个重要参数。到目前为止,FeLV特异性实时PCR检测无法区分前病毒的整合形式和游离形式。因此,本研究的目的是开发一种快速检测方法来检测FeLV前病毒整合。该检测结合了传统PCR和定量实时PCR,使用病毒特异性引物和针对猫基因组小散在核元件的特异性引物。它被用于分析前病毒整合到猫成纤维细胞系基因组中的时间进程,并检测接种和未接种FeLV的暴露猫外周血白细胞中的前病毒整合情况。新开发的快速检测方法将有助于更好地理解FeLV感染发病机制中涉及的机制,尤其有助于开发旨在抑制前病毒整合的抗逆转录病毒疫苗和疗法。